ChronicleAI
Science

Promising Leads Emerge in the Fight Against Pancreatic Cancer

By ChronicleAI11:40 UTC
Promising Leads Emerge in the Fight Against Pancreatic Cancer
AI-generated illustration. It does not depict real events.

Pancreatic cancer, a notoriously aggressive disease, continues to be a major health challenge, but recent research is offering new hope. Scientists are making strides in understanding the disease's biology, developing innovative treatments, and improving early detection methods. While the five-year survival rate remains relatively low, these advancements signal a potential turning point in the fight against this deadly cancer.

Understanding the Challenge

Pancreatic cancer is often diagnosed late, as it typically presents with vague symptoms that can be easily attributed to other conditions. This late diagnosis contributes to its poor prognosis. According to the American Cancer Society's Cancer Statistics 2025 report, the five-year relative survival rate for pancreatic cancer remains at 13%, and just 8% for pancreatic adenocarcinoma, the most common form. An estimated 67,440 Americans will be diagnosed with pancreatic cancer in 2025, and approximately 51,980 are expected to die from the disease. It is currently the third-leading cause of cancer-related deaths in the United States and is projected to become the second leading cause before 2030.

Advances in Treatment

Despite the challenges, significant progress has been made in developing new treatment options for pancreatic cancer. In 2024, there were four new drug approvals for pancreatic cancer, marking a record year. These include:

  • NALIRIFOX: In February 2024, the FDA approved Onivyde (liposomal irinotecan) as part of a treatment combination called NALIRIFOX for first-line therapy in patients with metastatic pancreatic cancer. NALIRIFOX includes Onivyde in combination with 5 fluorouracil (5-FU)/leucovorin and oxaliplatin. This provides a new treatment option for patients with newly diagnosed metastatic pancreatic cancer.
  • Targeted Therapies: As researchers learn more about the genetic mutations that drive pancreatic cancer, new drugs are being developed to target and treat specific types of the disease more effectively. Many pancreatic cancers are driven by mutations in the RAS family of oncogenes.
  • Tumor Treating Fields (TTFields): In December 2024, a Phase 3 trial showed that TTFields, in combination with chemotherapy, improved overall survival in unresectable, locally advanced pancreatic cancer. TTFields is a non-invasive therapy that uses low-intensity alternating electrical fields to disrupt tumor cell division.

Other innovative treatments include immunotherapy, which boosts the body's immune system to fight cancer, and stereotactic body radiotherapy (SBRT), a technique that delivers higher doses of radiation to the tumor while minimizing toxicity to surrounding organs.

Early Detection Efforts

Early detection is crucial for improving long-term survival in pancreatic cancer patients, as it allows for surgery, which can significantly increase life expectancy. Researchers are exploring various methods for early detection, including:

  • Liquid Biopsies: An investigational noninvasive exosome-based liquid biopsy shows potential for early detection of pancreatic cancer. When combined with the biomarker CA 19-9, the technique detected 97% of stage I and II pancreatic cancers in a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2024. Liquid biopsies allow for the detection of tumor-derived molecules in blood and other body fluids, aiding both early diagnosis and treatment monitoring.
  • Blood Biomarker Analysis with Pre-Diagnostic Imaging: A study at MD Anderson Cancer Center combines blood biomarker analysis with pre-diagnostic imaging, using artificial intelligence to analyze scans taken before and after individuals develop pancreatic cancer to identify early indicators of the disease.
  • PAC-MANN Test: A novel blood test called PAC-MANN (protease activity–based assay using a magnetic nanosensor) can detect changes in protease activity in the blood, correctly distinguishing patients with pancreatic ductal adenocarcinoma from healthy patients and those with noncancerous pancreatic issues 98% of the time. It also helped identify early-stage cancer with 85% accuracy when used along with the CA 19-9 test.
  • New Onset Diabetes (NOD) Study: The NCI-supported NOD Study is enrolling 10,000 people with new-onset diabetes or hyperglycemia to develop a blood test that can identify individuals who may need further testing for pancreatic cancer.
  • Using Indicators Such as Body Weight, Blood Sugar and Cholesterol: Researchers are focused on using indicators such as body weight, blood sugar and cholesterol to predict pancreatic cancer risk.

Research Funding and Collaboration

Increased research funding and collaboration are essential for accelerating progress in the fight against pancreatic cancer. Organizations like the Lustgarten Foundation, Pancreatic Cancer UK, and Pankind are providing significant funding for innovative research projects. The U.S. Army Medical Research Acquisition Activity (USAMRAA) is also soliciting applications for the fiscal year 2024 Pancreatic Cancer Research Program (PCARP). Collaborative efforts like the Pancreatic Cancer Detection Consortium (PCDC) are working to create a blood test that could pick up early pancreatic cancer in the general population.

A Glimmer of Hope

While pancreatic cancer remains a formidable foe, the recent advancements in treatment and early detection offer a glimmer of hope. The development of new drugs, the exploration of innovative therapies, and the progress in early detection methods are paving the way for improved outcomes for patients with pancreatic cancer. As research continues and funding increases, the future may hold even more effective strategies for combating this deadly disease. The rise in the five-year survival rate, though incremental, signals that progress is possible, and continued efforts are crucial to transforming pancreatic cancer into a more manageable and potentially curable condition.